These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 31060749)

  • 1. [Severity scores for childhood psoriasis: A systematic literature review].
    Lavaud J; Mahé E
    Ann Dermatol Venereol; 2019 Dec; 146(12):771-782. PubMed ID: 31060749
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Quality of Life and Improvement in Psoriasis Severity and Extent in Pediatric Patients.
    Bruins FM; Bronckers IMGJ; Groenewoud HMM; van de Kerkhof PCM; de Jong EMGJ; Seyger MMB
    JAMA Dermatol; 2020 Jan; 156(1):72-78. PubMed ID: 31774449
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Moderate Psoriasis: A Proposed Definition.
    Llamas-Velasco M; de la Cueva P; Notario J; Martínez-Pilar L; Martorell A; Moreno-Ramírez D
    Actas Dermosifiliogr; 2017 Dec; 108(10):911-917. PubMed ID: 28823420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the Dermatology Life Quality Index and the Children's Dermatology Life Quality Index in assessment of quality of life in patients with psoriasis aged 16-17 years.
    van Geel MJ; Maatkamp M; Oostveen AM; de Jong EM; Finlay AY; van de Kerkhof PC; Seyger MM
    Br J Dermatol; 2016 Jan; 174(1):152-7. PubMed ID: 26361284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between clinical response to therapy and health-related quality of life outcomes in patients with moderate to severe plaque psoriasis.
    Revicki DA; Willian MK; Menter A; Saurat JH; Harnam N; Kaul M
    Dermatology; 2008; 216(3):260-70. PubMed ID: 18187944
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psoriasis severity: commonly used clinical thresholds may not adequately convey patient impact.
    Golbari NM; van der Walt JM; Blauvelt A; Ryan C; van de Kerkhof P; Kimball AB
    J Eur Acad Dermatol Venereol; 2021 Feb; 35(2):417-421. PubMed ID: 32978847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What are the best outcome measures for assessing plaque psoriasis severity? A systematic review of the literature.
    Puzenat E; Bronsard V; Prey S; Gourraud PA; Aractingi S; Bagot M; Cribier B; Joly P; Jullien D; Le Maitre M; Paul C; Richard-Lallemand MA; Ortonne JP; Aubin F
    J Eur Acad Dermatol Venereol; 2010 Apr; 24 Suppl 2():10-6. PubMed ID: 20443995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between quality of life and the severity of psoriasis in Turkey.
    Çakmur H; Derviş E
    Eur J Dermatol; 2015 Apr; 25(2):169-76. PubMed ID: 25655046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Demographic characteristics and health-related quality of life of patients with moderate-to-severe psoriasis: The VACAP study.
    Daudén E; Pujol RM; Sánchez-Carazo JL; Toribio J; Vanaclocha F; Puig L; Yébenes M; Sabater E; Casado MA; Caloto MT; Aragón B;
    Actas Dermosifiliogr; 2013 Nov; 104(9):807-14. PubMed ID: 23827342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of treatments in daily clinical practice on the Children's Dermatology Life Quality Index in juvenile psoriasis: a longitudinal study from the Child-CAPTURE patient registry.
    Oostveen AM; de Jager ME; van de Kerkhof PC; Donders AR; de Jong EM; Seyger MM
    Br J Dermatol; 2012 Jul; 167(1):145-9. PubMed ID: 22616669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study.
    Shikiar R; Willian MK; Okun MM; Thompson CS; Revicki DA
    Health Qual Life Outcomes; 2006 Sep; 4():71. PubMed ID: 17005043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of three methods for measuring psoriasis severity in clinical studies (Part 2 of 2): use of quality of life to assess construct validity of the Lattice System Physician's Global Assessment, Psoriasis Area and Severity Index and Static Physician's Global Assessment.
    Simpson MJ; Chow C; Morgenstern H; Luger TA; Ellis CN
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1415-20. PubMed ID: 25917214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Etanercept and efalizumab for the treatment of psoriasis: a systematic review.
    Woolacott N; Hawkins N; Mason A; Kainth A; Khadjesari Z; Vergel YB; Misso K; Light K; Chalmers R; Sculpher M; Riemsma R
    Health Technol Assess; 2006 Nov; 10(46):1-233, i-iv. PubMed ID: 17083854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life and clinical features in Swedish children with psoriasis.
    Gånemo A; Wahlgren CF; Svensson Å
    Pediatr Dermatol; 2011; 28(4):375-9. PubMed ID: 21736605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
    Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
    J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The reliability of three psoriasis assessment tools: Psoriasis area and severity index, body surface area and physician global assessment.
    Bożek A; Reich A
    Adv Clin Exp Med; 2017 Aug; 26(5):851-856. PubMed ID: 29068583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measures used in specifying psoriasis lesion(s), global disease and quality of life: a systematic review.
    Garduno J; Bhosle MJ; Balkrishnan R; Feldman SR
    J Dermatolog Treat; 2007; 18(4):223-42. PubMed ID: 17671883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clear or almost clear skin improves the quality of life in patients with moderate-to-severe psoriasis: a systematic review and meta-analysis.
    Puig L; Thom H; Mollon P; Tian H; Ramakrishna GS
    J Eur Acad Dermatol Venereol; 2017 Feb; 31(2):213-220. PubMed ID: 27739123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
    Mattei PL; Corey KC; Kimball AB
    J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
    Chaptini C; Quinn S; Marshman G
    Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.